In-Hospital Initiation of Lipid-Lowering Therapy After Coronary Intervention as a Predictor of Long-term Utilization
Open Access
- 24 November 2003
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 163 (21) , 2576-2582
- https://doi.org/10.1001/archinte.163.21.2576
Abstract
DESPITE AN abundance of randomized trial data demonstrating the clinical benefits of lipid-lowering agents in patients with stable coronary disease,1-4 and preliminary data suggesting an early benefit in unstable coronary syndromes,5-7 these agents remain underused. Low rates of use of lipid-lowering agents are evident in large clinical trials,8 in prospective observational studies,9 at academic centers,10 in the community,11 in the United States,12,13 and abroad.14-16 Given the unequivocal reductions in cardiovascular morbidity and mortality afforded by these agents, interventions that improve their use are urgently needed.This publication has 1 reference indexed in Scilit:
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997